Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
Cadrenal Therapeutics (NASDAQ: CVKD) has successfully raised $5.1 million through an at-the-market (ATM) facility by selling 391,243 shares of common stock at an average price of $13.15 per share. Following this transaction, the company now has 1,496,771 shares outstanding and a cash balance of approximately $7.4 million. The funds will support the development of tecarfarin, a new vitamin K antagonist for patients with implanted cardiac devices or rare cardiovascular conditions, including preparation for a pivotal Phase 3 trial and ongoing partnering activities.
Cadrenal Therapeutics (NASDAQ: CVKD) ha raccolto con successo 5,1 milioni di dollari tramite un'operazione at-the-market (ATM), vendendo 391.243 azioni di capitale comune a un prezzo medio di 13,15 dollari per azione. A seguito di questa transazione, la società ha ora 1.496.771 azioni in circolazione e un saldo di cassa di circa 7,4 milioni di dollari. I fondi saranno utilizzati per supportare lo sviluppo di tecarfarin, un nuovo antagonista della vitamina K per pazienti con dispositivi cardiaci impiantati o rare condizioni cardiovascolari, compresa la preparazione per un trial cruciale di Fase 3 e attività di partenariato in corso.
Cadrenal Therapeutics (NASDAQ: CVKD) ha recaudado con éxito 5.1 millones de dólares a través de una instalación at-the-market (ATM) al vender 391,243 acciones de acciones comunes a un precio promedio de 13.15 dólares por acción. Tras esta transacción, la compañía ahora tiene 1,496,771 acciones en circulación y un saldo de efectivo de aproximadamente 7.4 millones de dólares. Los fondos apoyarán el desarrollo de tecarfarina, un nuevo antagonista de la vitamina K para pacientes con dispositivos cardíacos implantados o condiciones cardiovasculares raras, incluyendo la preparación para un ensayo clave de Fase 3 y actividades de asociación en curso.
Cadrenal Therapeutics (NASDAQ: CVKD)는 391,243주를 평균 주가 13.15달러에 판매하여 510만 달러를 성공적으로 모금했습니다. 이번 거래 이후 회사는 현재 1,496,771주의 발행주식이 있으며 약 740만 달러의 현금 잔고를 보유하고 있습니다. 이 자금은 심장 이식 장치를 가진 환자나 드문 심혈관 질환을 앓고 있는 환자를 위한 새로운 비타민 K 길항제인 테카르파린의 개발을 지원할 것이며, 3상 주요 임상시험 준비 및 지속적인 파트너십 활동에도 사용될 것입니다.
Cadrenal Therapeutics (NASDAQ: CVKD) a réussi à lever 5,1 millions de dollars par le biais d'une installation at-the-market (ATM) en vendant 391,243 actions ordinaires à un prix moyen de 13,15 dollars par action. Suite à cette transaction, la société a désormais 1 496 771 actions en circulation et un solde de trésorerie d'environ 7,4 millions de dollars. Les fonds soutiendront le développement de tecarfarin, un nouvel antagoniste de la vitamine K pour les patients porteurs de dispositifs cardiaques implantés ou de conditions cardiovasculaires rares, y compris la préparation pour un essai pivot de phase 3 et des activités de partenariat en cours.
Cadrenal Therapeutics (NASDAQ: CVKD) hat erfolgreich 5,1 Millionen Dollar durch eine At-the-Market (ATM) Finanzierung gesammelt, indem 391.243 Stück Stammaktien zu einem Durchschnittspreis von 13,15 Dollar pro Aktie verkauft wurden. Nach dieser Transaktion hat das Unternehmen nun 1.496.771 ausstehende Aktien und einen Kassenbestand von etwa 7,4 Millionen Dollar. Die Mittel werden die Entwicklung von Tecarfarin, einem neuen Vitamin-K-Antagonisten für Patienten mit implantierten Herzgeräten oder seltenen Erkrankungen des Herz-Kreislauf-Systems, unterstützen, einschließlich der Vorbereitung auf eine entscheidende Phase-3-Studie und laufende Partnerschaftsaktivitäten.
- Raised $5.1 million in additional capital through ATM facility
- Current cash balance increased to $7.4 million
- Successfully sold shares at $13.15 average price
- Dilution of existing shareholders through issuance of 391,243 new shares
Insights
The
This funding strengthens Cadrenal's financial position as they advance toward their pivotal Phase 3 trial for tecarfarin. For a small-cap biotech with a market cap of
Following the completion of the sales under the ATM facility, as of October 23, 2024, Cadrenal has 1,496,771 shares of common stock outstanding and a cash balance of approximately
"We are pleased to strengthen our balance sheet by efficiently using the ATM facility. The net proceeds provide us with added working capital as we continue developing tecarfarin, prepare for our pivotal Phase 3 trial, and progress our partnering activities," commented Quang X. Pham, Chief Executive Officer of Cadrenal.
The shares in the ATM facility were sold pursuant to a shelf registration statement declared effective by the
H.C. Wainwright & Co. acted as the exclusive sales agent for the ATM facility.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin, the most commonly used anticoagulant for these patients despite its prevalent side effects, drug-to-drug interactions and frequent dosing changes. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is planning pivotal clinical trials and pursuing clinical and commercial partnerships. The Company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. For more information, please visit: www.cadrenal.com.
SAFE HARBOR STATEMENT
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding continuing developing tecarfarin, preparing for the Company's pivotal trial and progress partnering activities, the Company's pursuit of clinical and commercial partnerships and the Company's study of tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to continue developing tecarfarin, preparing for the Company's pivotal trial, the Company's pursuit of clinical and commercial partnerships and the Company's study of tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties, and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's subsequent filings with the SEC, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-raises-5-1-million-via-at-the-market-facility-302285248.html
SOURCE Cadrenal Therapeutics, Inc.
FAQ
How much did Cadrenal Therapeutics (CVKD) raise through its ATM facility in October 2024?
What is the current cash balance of Cadrenal Therapeutics (CVKD) after the ATM facility raise?
How many shares of common stock does Cadrenal Therapeutics (CVKD) have outstanding after the ATM facility?